-
Original Article
Therapeutic resources used by physiotherapists for the relief of labor pain: a cross-sectional study
- Alessandra de Campos Gonçalves
, - Giovana Garçoni Poli ,
- Clara Maria de Araujo Silva ,
- Ana Carolina Sartorato Beleza ,
- Richard Eloin Liebano
01-23-2025
Summary
Original ArticleTherapeutic resources used by physiotherapists for the relief of labor pain: a cross-sectional study
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo99
01-23-2025- Alessandra de Campos Gonçalves ,
- Giovana Garçoni Poli ,
- Clara Maria de Araujo Silva ,
- Ana Carolina Sartorato Beleza ,
- Richard Eloin Liebano
Views183Abstract
Objective
The aim of the study was to identify non-pharmacological therapeutic resources used by physiotherapists for pain relief during labor and childbirth.
Methods
This is a cross-sectional study conducted from January to March 2021, followed the STROBE guidelines. It included Brazilian physiotherapists with a minimum of two years in obstetric care experience. Data were collected using a 33-item online questionnaire, which covered sociodemographic details and the utilization of non-pharmacological resources. Descriptive analysis was used to determine participant characteristics. Associations between sociodemographic variables, specialist titles, participation in scientific events, and methods for pain relief methods during childbirth were assessed using chi-square or Fisher’s exact tests. Data were analyzed using SPSS version 23.0, with a significance level set at 5% (p < 0.05).
Results
A total of 114 Brazilian physiotherapists participated in this study. Participants chose to utilize non-pharmacological therapies and resources that are within the scope of physiotherapists’ practice for labor pain. Kinesiotherapy with the use of devices was the most employed technique for pain relief during the birthing process.
Conclusion
The study highlights the prevalent use of non-pharmacological therapeutic resources, particularly kinesiotherapy with devices, among Brazilian physiotherapists for labor pain relief.
Key-words childbirthlabor painLabor, obstetricNon-pharmacological resourcespain managementParturiationPhysical therapistsPregnancysurveys and questionnairesSee more
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Alessandra de Campos Gonçalves
-
Original Article
Maternal erythrocytosis as a risk factor for small for gestational age at term in high altitude
- Wilfredo Villamonte-Calanche ,
- Marco Antonio Salazar-Zegarra ,
- Cleto De-la-Torre-Dueñas ,
- Alexandra Villamonte-Jerí ,
- Adaí Vera-Luza , [ … ],
- Nuria Huanca-Huirse
01-23-2025
Summary
Original ArticleMaternal erythrocytosis as a risk factor for small for gestational age at term in high altitude
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo98
01-23-2025- Wilfredo Villamonte-Calanche ,
- Marco Antonio Salazar-Zegarra ,
- Cleto De-la-Torre-Dueñas ,
- Alexandra Villamonte-Jerí ,
- Adaí Vera-Luza ,
- Milagros Hilari Bustinza-Apaza ,
- Nuria Huanca-Huirse
Views194Abstract
Objective
To determine if maternal erythrocytosis is a risk factor for small-for-gestational age at term at 3,400-m altitude in pregnant women without intercurrent disease.
Methods
Analytical study of retrospective cohorts at Cusco, a city at 3,400-m altitude. Our participants were 224 and 483 pregnant women with and without exposure to maternal erythrocytosis, respectively. A logistic regression with the goodness of fit to the proposed model was also performed with the Hosmer and Lemeshow test, evaluating the small-for-gestational-age results with or without exposure to hemoglobin >14.5 g/dl.
Results
The incidence of small-for-gestational-age was 6.9% for this entire cohort. The maternal erythrocytosis during gestation without any maternal morbidity at 3,400-m altitude has an ORa=0.691 (p=0.271) for small-for-gestational-age at term. Inadequate prenatal control has an ORa=2.115 (p=0.016) for small-for-gestational-age compared to adequate prenatal control.
Conclusion
Maternal erythrocytosis in pregnant women without any morbidity is not a risk factor for small-for-gestational-age at 3,400 m-altitude.
Key-words AltitudeFetal growth retardationGestational agehemoglobinHypoxiaMorbidityNeonatal mortalityPolycythemiaPregnancyPregnant womenRisk factorssmall for gestational ageSee moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Wilfredo Villamonte-Calanche
-
Original Article
Comparison of serum ischemia modified albumin levels between preeclamptic and healthy pregnant women
- Dinç Zuhal ,
- Çakar Erbil ,
- Kumru Pınar ,
- Erel Özcan ,
- Neşelioğlu Salim , [ … ],
- Boz Gizem
01-23-2025
Summary
Original ArticleComparison of serum ischemia modified albumin levels between preeclamptic and healthy pregnant women
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo97
01-23-2025Views222See moreAbstract
Objective
Our aims to compare level of serum ischemia modified albümin(IMA) between healthy and preeclamptic pregnancies and to evaluate the relationship of IMA with preeclampsia, preeclampsia severity and perinatal outcomes.
Methods
Our study is a prospective case-control study. A total of 134 pregnant women (66 preeclamptic and 68 healthy pregnant) between 18-45 years of age and between 24- 41 gestational weeks participated. Serum IMA levels were measured by the Albumin Cobalt Binding (ACB) test.
Results
The mean IMA values were found to be significantly higher in the preeclampsia group compared to the control group (p<0,001). Patients were divided into 3 groups; severe preeclampsia(n=29), non-severe preeclampsia(n=37) and healthy pregnant(n=68). Statistically significant difference was not found between severe preeclampsia and non-severe preeclampsia (p=0.505). The performance of IMA values in predicting the development of preeclampsia among all participants was evaluated with Receiver Operating Characteristic (ROC) analysis. According to the ROC analysis, the best cut-off value at which the maximum area under the curve (AUC) was obtained was found when IMA>0.98(AUC: 0.690 95% Confidence Interval (CI): 0.600-0.781 p<0.001). When IMA threshold value of >0.98 was taken to predict preeclampsia; the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated as 65.15%, 64.71%, 64.18%, and 65.67%, respectively.
Conclusion
IMA level may be a useful new marker in recognizing and predicting preeclampsia. However, despite the power of recognizing the disease, serum IMA levels do not give an idea about the severity of the disease. More comprehensive studies are needed in order to use IMA levels in the diagnosis of preeclampsia.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Dinç Zuhal
-
Nominata 2024
Nominata 2024
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:eRBGO20242024
12-31-2024
Summary
Nominata 2024Nominata 2024
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:eRBGO20242024
12-31-2024DOI 10.61622/rbgo/2024nominata02024
Views107We wish to thank everyone who contributed to the edition of the Revista Brasileira de Ginecologia e Obstetrícia – RBGO volume 46, year 2024, especially the authors and reviewers whose work and opinions were essential to maintain the scientific and methodological rigor of the published articles.A. Seval Ozgu-Erdinc, University of Health Sciences, Ankara Eğitim ve […]See moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Letter to the Editor
Comment on: Effect of combined training on body image, body composition and functional capacity in patients with breast cancer: controlled clinical trial
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo96
12-04-2024
Summary
Letter to the EditorComment on: Effect of combined training on body image, body composition and functional capacity in patients with breast cancer: controlled clinical trial
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo96
12-04-2024Views144Dear Editor,I am writing to express my appreciation for the recent article titled “Effect of Combined Training on Body Image, Body Composition, and Functional Capacity in Patients with Breast Cancer: Controlled Clinical Trial,” published online on June 20, 2023. The study provides crucial insights into the benefits of combined training for breast cancer patients, highlighting […]See moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Original Article
Prognosis and cardiotoxicity associated to adjuvant trastuzumab for breast cancer: real world study in a public health system
- Ana Elisa Ribeiro da Silva Cabello ,
- César Cabello ,
- Susana Oliveira Botelho Ramalho ,
- Otávio Rizzi Coelho ,
- Otávio Rizzi Coelho-Filho , [ … ],
- Luiz Carlos Zeferino
12-04-2024
Summary
Original ArticlePrognosis and cardiotoxicity associated to adjuvant trastuzumab for breast cancer: real world study in a public health system
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo93
12-04-2024- Ana Elisa Ribeiro da Silva Cabello ,
- César Cabello ,
- Susana Oliveira Botelho Ramalho ,
- Otávio Rizzi Coelho ,
- Otávio Rizzi Coelho-Filho ,
- Helymar da Costa Machado ,
- Délio Marques Conde ,
- Luiz Carlos Zeferino
Views158Abstract
Objective:
To analyze the prognosis of patients with breast cancer who developed trastuzumab-induced cardiotoxicity and to analyze factors associated with and resulting from cardiotoxicity.
Methods:
This was a retrospective cohort study that included 255 HER2-positive breast cancer patients who received adjuvant trastuzumab therapy. The inclusion criteria were a diagnosis of HER2-positive breast cancer and adjuvant trastuzumab therapy; disease stage I-III; <70 years; and a baseline echocardiogram showing a left ventricular ejection fraction (LVEF) ≥ 55%. The Kaplan-Meier method, the log-rank test, and the Cox proportional hazards model were used.
Results:
In all, 15.3% (39/255) of patients presented with cardiotoxicity. Treatment was suspended in 92.3% (36/39) of patients who presented with cardiotoxicity during trastuzumab treatment. The treatment was suspended in 46 of 255 patients and it was permanently interrupted in 84.8% (33/46) of these patients, with 84.8% (28/33) due to cardiotoxicity. Cardiotoxicity was not associated with disease-free survival (DFS) (hazard ratio (HR) = 1.48; 95% confidence interval (CI = 0.79-2.78) or overall survival (OS) (HR = 1.68; 95%CI= 0.83-3.41). Patients with clinical stage III and whom trastuzumab therapy was suspended (all causes) had worse DFS; (HR = 3.19; 95% CI=1.77-5.74) and (HR = 1.83; 95% CI=1.01-3.32) respectively. Those with clinical stage III and whom trastuzumab therapy was permanently interrupted had worse OS; (HR = 3.80; 95% CI =1.82-7.94), and (HR = 2,26; 95% CI =1.09-4.68 respectively.
Conclusion:
Cardiotoxicity was not associated with DFS or OS. Clinical stage III, Suspension and permanent interruption of treatment regardless of the cause were associated with worse DFS and OS in breast cancer patients.
Key-words Breast neoplasmsCardiotoxicityChemotherapyDisease-free survivalPrognosisTrastuzumabUnified Health SystemSee moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Ana Elisa Ribeiro da Silva Cabello
-
Original Article
Clinical, histopathological and immunohistochemical analysis of vulvar squamous cell carcinoma
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo91
12-04-2024
Summary
Original ArticleClinical, histopathological and immunohistochemical analysis of vulvar squamous cell carcinoma
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo91
12-04-2024Views142See moreAbstract
Objective:
The average age of patients with vulvar squamous cell carcinoma (SCC) has been reported to have declined. Human papilloma virus (HPV)-related lesions have been shown to be associated with the expression of the immunohistochemical (IHC) marker p16. Non-HPV-related tumors have been characterized by p53 abnormal expression and PDL1 expression. We aimed to evaluate the correlation between these markers and vulvar SCC and to relate it to the clinical and pathological characteristics.
Methods:
Histopathologic assessments and IHC analyses of p16, p53, and PDL1 were performed in 41 samples of vulvar SCC collected between 2016 and 2021. The data were correlated with clinical and pathological characteristics of the patients.
Results:
The mean age of the patients was 72.1 years. Positive p16 and PDL1 staining was detected in 24.4% and 17.1% of the samples, respectively. p53 expression was negative in 19.5% of the samples, whereas it was overexpressed in 24.4%. p16-positive tumors showed a smaller depth of invasion (DOI) (p = 0.014), while tumors with p53 abnormal expression showed greater DOI (p = 0.041). PDL1 expression was correlated with increased number of inflammatory cells (p = 0.055). In addition, lesions with lymphovascular space invasion were p16-negative.
Conclusion:
In our sample, regarding to the SCC incidence the patients’ mean age did not change. The expression of p16 was inversely correlated with p53 results. Tumors with p53 abnormal expression and absence of p16 showed a greater DOI. Our data suggest an association between PDL1 expression and increased inflammatory infiltrates in vulvar SCC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Review Article
Metformin versus insulin in gestational diabetes mellitus: a systematic review
- Giovanna Noronha Berti ,
- Igor Gutschov Oviedo Garcia ,
- João Pedro Ruas Floriano de Toledo ,
- Júlia Rodrigues Tatemoto ,
- Lais Watanabe Marino , [ … ],
- Sérgio Floriano de Toledo
12-04-2024
Summary
Review ArticleMetformin versus insulin in gestational diabetes mellitus: a systematic review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo89
12-04-2024- Giovanna Noronha Berti ,
- Igor Gutschov Oviedo Garcia ,
- João Pedro Ruas Floriano de Toledo ,
- Júlia Rodrigues Tatemoto ,
- Lais Watanabe Marino ,
- Mariana de Medeiros Legori ,
- Sérgio Floriano de Toledo
Views220See moreAbstract
Objective:
The aim of this study is to assess the use of metformin with or without insulin for the treatment of Gestational Diabetes Mellitus compared to insulin alone.
Data sources:
This article consists of a systematic review of randomized clinical trials. The searches were carried out on MEDLINE including 7 studies, between 2010 to 2021.
Study selection:
Randomized clinical trials comparing metformin and insulin written in English, Spanish or Portuguese, with no time limit, were included.
Data collection:
Data was extracted from all the 7 articles and compared statistically when possible. Whenever data was not available or couldn’t be statistically compared, the main results were described in detail.
Data synthesis:
Insulin alone is not superior than metformin with or without insulin on gestational diabetes mellitus.
Conclusion:
There is a potential viability of using metformin as an alternative compared to insulin alone in the treatment of Gestational Diabetes Mellitus. However, all assessed outcomes have a very low level of certainty of evidence and more studies are necessary to support these findings.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Giovanna Noronha Berti
Search
Search in:
Tag Cloud
Pregnancy (251)Breast neoplasms (104)Pregnancy complications (103)Risk factors (103)Menopause (87)Ultrasonography (83)Cesarean section (77)Prenatal care (71)Endometriosis (70)Obesity (60)Infertility (56)Quality of life (53)prenatal diagnosis (51)Women's health (48)Maternal mortality (45)Pregnant women (45)Breast (44)Postpartum period (44)Uterine cervical neoplasms (43)Prevalence (42)